General medical conditions in 347 bipolar disorder patients: Clinical correlates of metabolic and autoimmune-allergic diseasesJOURNAL OF AFFECTIVE DISORDERSIF4.92015-01-0187PREAI
Study of the binding interaction between fluorinated matrix metalloproteinase inhibitors and Human Serum AlbuminEUROPEAN JOURNAL OF MEDICINAL CHEMISTRYIF5.92014-05-0113PREAI
Selective Arylsulfonamide Inhibitors of ADAM-17: Hit Optimization and Activity in Ovarian Cancer Cell ModelsJOURNAL OF MEDICINAL CHEMISTRYIF6.82013-10-0423OA
Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: Synthesis and biological evaluationEUROPEAN JOURNAL OF MEDICINAL CHEMISTRYIF5.92013-04-0136PREAI
Synthesis and Preliminary Evaluation in Tumor Bearing Mice of New 18F-Labeled Arylsulfone Matrix Metalloproteinase Inhibitors as Tracers for Positron Emission TomographyJOURNAL OF MEDICINAL CHEMISTRYIF6.82013-03-1918PREAI
Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: A first round of lead optimizationEUROPEAN JOURNAL OF MEDICINAL CHEMISTRYIF5.92012-01-0127PREAI
Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene) sulfonamido-based hydroxamates as matrix metalloproteinase inhibitorsEUROPEAN JOURNAL OF MEDICINAL CHEMISTRYIF5.92011-07-0134OAAI
Potent Arylsulfonamide Inhibitors of Tumor Necrosis Factor-α Converting Enzyme Able to Reduce Activated Leukocyte Cell Adhesion Molecule Shedding in Cancer Cell ModelsJOURNAL OF MEDICINAL CHEMISTRYIF6.82010-02-2434PREAI
Design, Synthesis, Biological Evaluation, and NMR Studies of a New Series of Arylsulfones As Selective and Potent Matrix Metalloproteinase-12 InhibitorsJOURNAL OF MEDICINAL CHEMISTRYIF6.82009-09-2353PREAI
N-O-Isopropyl Sulfonamido-Based Hydroxamates: Design, Synthesis and Biological Evaluation of Selective Matrix Metalloproteinase-13 Inhibitors as Potential Therapeutic Agents for OsteoarthritisJOURNAL OF MEDICINAL CHEMISTRYIF6.82009-07-1658PREAI